Walleye Capital LLC Editas Medicine, Inc. Transaction History

Walleye Capital LLC

$24 Billion
Q3 2025

A detailed history of Walleye Capital LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 132,600 shares of EDIT stock, worth $344,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares

132,600

Holding current value

$344,760

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.2 - $3.52 $866,426 - $1.39 Million	393,830 New	393,830 $1.37 Million
Q4 2024 Feb 13, 2025	SELL	$1.2 - $3.76 $98,017 - $307,120	-81,681 Reduced 87.52%	11,646 $14,000
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $316,378 - $556,228	93,327 New	93,327 $318,000
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $135,404 - $213,219	19,261 New	19,261 $142,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $172,600 - $283,084	24,552 Added 200.98%	36,768 $266,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $838,356 - $1.33 Million	-100,764 Reduced 89.19%	12,216 $108,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.37 Million - $2.19 Million	112,980 New	112,980 $1.38 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $116,161 - $215,620	-6,279 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $88,967 - $195,991	5,979 Added 1993.0%	6,279 $125,000
Q4 2019 Feb 14, 2020	SELL	$19.49 - $32.63 $71,781 - $120,176	-3,683 Reduced 92.47%	300 $9,000
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $74,059 - $88,285	3,293 Added 477.25%	3,983 $91,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $13,406 - $18,222	690 New	690 $17,000

Others Institutions Holding EDIT

# of Institutions

217

Shares Held

48M

Call Options Held

637K

Put Options Held

292K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $179M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account